Literature DB >> 21502308

Lysosomal lipid storage diseases.

Heike Schulze1, Konrad Sandhoff.   

Abstract

Lysosomal lipid storage diseases, or lipidoses, are inherited metabolic disorders in which typically lipids accumulate in cells and tissues. Complex lipids, such as glycosphingolipids, are constitutively degraded within the endolysosomal system by soluble hydrolytic enzymes with the help of lipid binding proteins in a sequential manner. Because of a functionally impaired hydrolase or auxiliary protein, their lipid substrates cannot be degraded, accumulate in the lysosome, and slowly spread to other intracellular membranes. In Niemann-Pick type C disease, cholesterol transport is impaired and unesterified cholesterol accumulates in the late endosome. In most lysosomal lipid storage diseases, the accumulation of one or few lipids leads to the coprecipitation of other hydrophobic substances in the endolysosomal system, such as lipids and proteins, causing a "traffic jam." This can impair lysosomal function, such as delivery of nutrients through the endolysosomal system, leading to a state of cellular starvation. Therapeutic approaches are currently restricted to mild forms of diseases with significant residual catabolic activities and without brain involvement.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502308      PMCID: PMC3098676          DOI: 10.1101/cshperspect.a004804

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  140 in total

Review 1.  A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.

Authors:  Jian-Qiang Fan
Journal:  Biol Chem       Date:  2008-01       Impact factor: 3.915

Review 2.  Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids.

Authors:  Thomas Kolter; Konrad Sandhoff
Journal:  Annu Rev Cell Dev Biol       Date:  2005       Impact factor: 13.827

3.  Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.

Authors:  D Elstein; C Hollak; J M F G Aerts; S van Weely; M Maas; T M Cox; R H Lachmann; M Hrebicek; F M Platt; T D Butters; R A Dwek; A Zimran
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 4.  Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking.

Authors:  Judith Storch; Zhi Xu
Journal:  Biochim Biophys Acta       Date:  2009-02-13

5.  G(M1)-ganglioside degradation and biosynthesis in human and murine G(M1)-gangliosidosis.

Authors:  Renata Sano; Vera M T Trindade; Alessandra Tessitore; Alessandra d'Azzo; Matheus B Vieira; Roberto Giugliani; Janice C Coelho
Journal:  Clin Chim Acta       Date:  2005-01-26       Impact factor: 3.786

6.  Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.

Authors:  Elena Elliot-Smith; Anneliese O Speak; Emyr Lloyd-Evans; David A Smith; Aarnoud C van der Spoel; Mylvaganam Jeyakumar; Terry D Butters; Raymond A Dwek; Alessandra d'Azzo; Frances M Platt
Journal:  Mol Genet Metab       Date:  2008-04-01       Impact factor: 4.797

7.  Critical role of iron in the pathogenesis of the murine gangliosidoses.

Authors:  Mylvaganam Jeyakumar; Ian Williams; David Smith; Timothy M Cox; Frances M Platt
Journal:  Neurobiol Dis       Date:  2009-06       Impact factor: 5.996

8.  Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in mouse.

Authors:  Junko Matsuda; Makiko Kido; Keiko Tadano-Aritomi; Ineo Ishizuka; Kumiko Tominaga; Kazunori Toida; Eiji Takeda; Kunihiko Suzuki; Yasuhiro Kuroda
Journal:  Hum Mol Genet       Date:  2004-09-02       Impact factor: 6.150

9.  Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity.

Authors:  C Aslanidis; S Ries; P Fehringer; C Büchler; H Klima; G Schmitz
Journal:  Genomics       Date:  1996-04-01       Impact factor: 5.736

10.  Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.

Authors:  T Heare; N J Alp; D A Priestman; A B Kulkarni; P Qasba; T D Butters; R A Dwek; K Clarke; K M Channon; F M Platt
Journal:  J Inherit Metab Dis       Date:  2006-12-25       Impact factor: 4.982

View more
  56 in total

1.  The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian α-linked glycosylceramides.

Authors:  Lisa Kain; Bill Webb; Brian L Anderson; Shenglou Deng; Marie Holt; Anne Costanzo; Anne Constanzo; Meng Zhao; Kevin Self; Anais Teyton; Chris Everett; Mitchell Kronenberg; Dirk M Zajonc; Albert Bendelac; Paul B Savage; Luc Teyton
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

2.  A Short Synthetic Peptide Mimetic of Apolipoprotein A1 Mediates Cholesterol and Globotriaosylceramide Efflux from Fabry Fibroblasts.

Authors:  Ulrike Schueler; Christine Kaneski; Alan Remaley; Stephen Demosky; Nancy Dwyer; Joan Blanchette-Mackie; John Hanover; Roscoe Brady
Journal:  JIMD Rep       Date:  2015-12-19

Review 3.  Lysosomal physiology.

Authors:  Haoxing Xu; Dejian Ren
Journal:  Annu Rev Physiol       Date:  2015       Impact factor: 19.318

4.  Port-to-port delivery: Mobilization of toxic sphingolipids via extracellular vesicles.

Authors:  Giuseppe Scesa; Ana Lis Moyano; Ernesto R Bongarzone; Maria I Givogri
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

5.  Fluid levity of the cell: Role of membrane lipid architecture in genetic sphingolipidoses.

Authors:  Ludovic D'Auria; Ernesto R Bongarzone
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

6.  Membrane lipids regulate ganglioside GM2 catabolism and GM2 activator protein activity.

Authors:  Susi Anheuser; Bernadette Breiden; Günter Schwarzmann; Konrad Sandhoff
Journal:  J Lipid Res       Date:  2015-07-14       Impact factor: 5.922

Review 7.  Glycosphingolipid functions.

Authors:  Clifford A Lingwood
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

8.  δ-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders.

Authors:  Miao Xu; Ke Liu; Manju Swaroop; Forbes D Porter; Rohini Sidhu; Sally Firnkes; Sally Finkes; Daniel S Ory; Juan J Marugan; Jingbo Xiao; Noel Southall; William J Pavan; Cristin Davidson; Steven U Walkley; Alan T Remaley; Ulrich Baxa; Wei Sun; John C McKew; Christopher P Austin; Wei Zheng
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

Review 9.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

10.  Release of Mediator Enzyme β-Hexosaminidase and Modulated Gene Expression Accompany Hemocyte Degranulation in Response to Parasitism in the Silkworm Bombyx mori.

Authors:  Shambhavi H Prabhuling; Pooja Makwana; Appukuttan Nair R Pradeep; Kunjupillai Vijayan; Rakesh Kumar Mishra
Journal:  Biochem Genet       Date:  2021-02-22       Impact factor: 1.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.